Company intelligence / Profile preview

PapiVax Biotech, Inc.

Ownership: Private
Development stage: Phase 2

Overview

PBI has multiple Phase II clinical candidates targeting HPV infections and HPV-related cancers. The company expects to have Phase II data from all three of its core HPV franchise candidates by Q4 2026.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DNA vaccinesviral vector vaccinesnucleic acid-based immunotherapeutics
Industry: Biotech

Drug pipeline

7 assets

pBI-11

6 more assets in the full pipeline.

Request access →

Partnerships

Cancer Research UK (licensed TA-HPV viral vector)

Beyond the preview

Go deeper on PapiVax Biotech, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PapiVax Biotech, Inc..

Explore the full profile